<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998283</url>
  </required_header>
  <id_info>
    <org_study_id>09-HM10460A-102</org_study_id>
    <nct_id>NCT00998283</nct_id>
  </id_info>
  <brief_title>Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HM10460A (HNK460) When Administered Subcutaneously to Healthy Adult Korean Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Study Design

             -  Randomized, Double-blind, Placebo-controlled, escalating single-dose design.

             -  Five ascending dose cohorts.

             -  In each cohort, subjects will be randomized to receive a single dose of HM10460A or
                placebo (negative control)

        -  Objectives

             -  The primary objective of the study is to assess the safety and tolerability of
                single escalating subcutaneous doses of HM10460A in healthy adult Korean Subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of the study are as follows:

        -  to assess the pharmacokinetics (PK) of a single subcutaneous dose of HM10460A.

        -  to assess the relationship between the serum concentration of HM10460A and absolute
           neutrophil count (ANC).

        -  to assess the relationship between the serum concentration of HM10460A and CD34+ cell
           counts in the blood.

        -  to assess the immunogenicity (HM10460A, native G-CSF antibody,neutralizing antibodies)
           of a single subcutaneous dose of HM10460A.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety data, including physical examinations (to include injection site reactions and splenic evaluations), laboratory evaluations, ECGs, vital signs, and adverse effects (AEs)</measure>
    <time_frame>Time point of collection, where appropriate</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Samples for immunogenicity</measure>
    <time_frame>Time point of collection, where appropriate</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum PK parameters/Urine PK parameters</measure>
    <time_frame>Serum : pre-dose, 0.25, 05, 0.75, 1,2,3,4,6,8,12,16,24,36,48,72,96,120,144 (hr)// Urine : 0-6, 6-12, 12-24, 24-36, 36,48(hr)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of the ANC (Absolute Neutrophil count) &amp; CD34+ cell.</measure>
    <time_frame>Pre-dose, 24 and 48 hours post-dose, on return Days 4,5,6,7,11,15 and 22</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM10460A 5μg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM10460A 15μg/kg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM10460A 45μg/kg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM10460A 135μg/kg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of HM10460A 350μg/kg or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A 5μg/kg</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A 15μg/kg</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A 45μg/kg</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A 135μg/kg</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A 350μg/kg</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneously administrate at 0 hour on Day 1</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult Korean male and/or females, 20 - 45 years of age(inclusive).

          -  BMI of 18 - 27kg/m2.

          -  Medically healthy with no clinically significant screening results.

          -  The following results in laboratory test

               -  Absolute neutrophil count (ANC) : 2000 ~ 7500/mm3

          -  Non-smokers or subjects who smoke less than 10 cigarettes/day

          -  After a confirmed menstrual period, females of childbearing potential must be either
             sexually inactive (abstinent) for 14 days prior to screening and agree to remain so
             throughout the study, or have been using a highly effective method of birth control,
             such as the following examples:

               -  intra-uterine device in place for at least 3 months prior to Day 1;

               -  stable hormonal contraceptive for at least 3 months prior to Day 1 through
                  completion of study;

               -  surgical sterilization (vasectomy) of partner at least 6 months prior to Day 1.

          -  Females of non-childbearing potential must have undergone one of the following
             sterilization procedures at least 6 months prior to Day 1:

               -  bilateral tubal ligation;

               -  hysterectomy;

               -  hysterectomy with unilateral or bilateral oophorectomy;

               -  bilateral oophorectomy.

        Exclusion Criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,
             or psychiatric disease.

          -  Positive urine drug/alcohol testing at screening or check-in.

          -  Positive testing for HIV, HBsAg, or HCV antibodies.

          -  Active infection

          -  Positive testing for palpable spleen at screening or check-in.

          -  The following results in laboratory test:

               -  WBC &gt; 10.0 x 10^3/mm3

               -  Hb &lt; 13g/dL

               -  Platelet &lt; 150 x 10^3/mm3

               -  AST/ALT &gt; 50 IU/L

          -  History or presence of alcoholism or drug abuse within 2 years prior to Day 1.

          -  History of G-CSF-related product use (i.e., pegfilgrastim, filgrastim).

          -  History of anaphylactic reaction to medicine or environmental exposures.

          -  Use of any prescription medication (with the exception of hormonal contraceptives for
             females) or receipt of any blood products within 14 days prior to Day 1.

          -  Use of any over-the-counter medication, including herbal products, within 7 days prior
             to the Day 1. Up to 2 grams per day of acetaminophen is allowed at the discretion of
             the Investigator.

          -  Blood donation or significant blood loss within 56 days prior to Day 1.

          -  Plasma donation within 7 days prior to Day 1.

          -  Participation in another clinical trial (receipt of last investigational medication)
             within 30 days prior to Day 1.

          -  Females who are pregnant or lactating.

          -  Subjects who are unlikely to comply with the protocol requirements, instructions and
             study related restrictions; e.g., uncooperative attitude, inability to return for
             follow-up visits and improbability of completing the clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanmi Clinical</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2009</study_first_submitted>
  <study_first_submitted_qc>October 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2009</study_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

